Antiemesis, version 2.2017 featured updates to the NCCN guidelines

Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Lawrence Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim NoonanEric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, Miranda Hughes

Research output: Contribution to journalReview article

59 Scopus citations


The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis address all aspects of management for chemotherapy-induced nausea and vomiting. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for Antiemesis, specifically those regarding carboplatin, granisetron, and olanzapine.

Original languageEnglish (US)
Pages (from-to)883-893
Number of pages11
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number7
StatePublished - Jul 1 2017


ASJC Scopus subject areas

  • Oncology

Cite this

Berger, M. J., Ettinger, D. S., Aston, J., Barbour, S., Bergsbaken, J., Bierman, P. J., Brandt, D., Dolan, D. E., Ellis, G., Kim, E. J., Kirkegaard, S., Kloth, D. D., Lagman, R., Lim, D., Loprinzi, C. L., Ma, C. X., Maurer, V., Michaud, L. B., Nabell, L. M., ... Hughes, M. (2017). Antiemesis, version 2.2017 featured updates to the NCCN guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 15(7), 883-893.